Titre : Épilepsies myocloniques

Épilepsies myocloniques : Questions médicales fréquentes

Termes MeSH sélectionnés :

Ganoderma
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Épilepsies myocloniques : Questions médicales les plus fréquentes", "headline": "Épilepsies myocloniques : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Épilepsies myocloniques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-27", "dateModified": "2025-04-23", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Syndromes épileptiques", "url": "https://questionsmedicales.fr/mesh/D000073376", "about": { "@type": "MedicalCondition", "name": "Syndromes épileptiques", "code": { "@type": "MedicalCode", "code": "D000073376", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.140.490.493" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Épilepsies myocloniques progressives", "alternateName": "Myoclonic Epilepsies, Progressive", "url": "https://questionsmedicales.fr/mesh/D020191", "about": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques progressives", "code": { "@type": "MedicalCode", "code": "D020191", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.140.490.493.063.650" } } }, { "@type": "MedicalWebPage", "name": "Épilepsie myoclonique juvénile", "alternateName": "Myoclonic Epilepsy, Juvenile", "url": "https://questionsmedicales.fr/mesh/D020190", "about": { "@type": "MedicalCondition", "name": "Épilepsie myoclonique juvénile", "code": { "@type": "MedicalCode", "code": "D020190", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C10.228.140.490.493.063.670" } } } ], "about": { "@type": "MedicalCondition", "name": "Épilepsies myocloniques", "alternateName": "Epilepsies, Myoclonic", "code": { "@type": "MedicalCode", "code": "D004831", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Pasquale Striano", "url": "https://questionsmedicales.fr/author/Pasquale%20Striano", "affiliation": { "@type": "Organization", "name": "IRCCS Istituto \"Giannina Gaslini\", Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy." } }, { "@type": "Person", "name": "Marte Syvertsen", "url": "https://questionsmedicales.fr/author/Marte%20Syvertsen", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway." } }, { "@type": "Person", "name": "Deb K Pal", "url": "https://questionsmedicales.fr/author/Deb%20K%20Pal", "affiliation": { "@type": "Organization", "name": "Department of Basic & Clinical Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK." } }, { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Jeanette Koht", "url": "https://questionsmedicales.fr/author/Jeanette%20Koht", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion.", "datePublished": "2022-09-28", "url": "https://questionsmedicales.fr/article/36271550", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.biopha.2022.113766" } }, { "@type": "ScholarlyArticle", "name": "A novel mucosal bivalent vaccine of EV-A71/EV-D68 adjuvanted with polysaccharides from Ganoderma lucidum protects mice against EV-A71 and EV-D68 lethal challenge.", "datePublished": "2023-12-18", "url": "https://questionsmedicales.fr/article/38110940", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12929-023-00987-3" } }, { "@type": "ScholarlyArticle", "name": "A nanozyme multifunctional platform based on iron doped carbon dots derived from Tibetan Ganoderma lucidum waste for glucose sensing, anti-counterfeiting applications, and anticancer cell effect.", "datePublished": "2024-05-15", "url": "https://questionsmedicales.fr/article/38761660", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.talanta.2024.126262" } }, { "@type": "ScholarlyArticle", "name": "Corrigendum to \"Ganoderic acids-rich ethanol extract from Ganoderma lucidum protects against alcoholic liver injury and modulates intestinal microbiota in mice with excessive alcohol intake\" [Curr. Res. Food Sci. 5(2022) 515-530].", "datePublished": "2022-07-14", "url": "https://questionsmedicales.fr/article/35865804", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.crfs.2022.07.001" } }, { "@type": "ScholarlyArticle", "name": "Synergy of de-walled Ganoderma Lucidum spore powder (GLSP) on targeted therapy in advanced non-squamous non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutant: protocol for a randomized, double-blind, placebo-controlled study.", "datePublished": "2024-03-18", "url": "https://questionsmedicales.fr/article/38500118", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12906-024-04416-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système nerveux", "item": "https://questionsmedicales.fr/mesh/D009422" }, { "@type": "ListItem", "position": 3, "name": "Maladies du système nerveux central", "item": "https://questionsmedicales.fr/mesh/D002493" }, { "@type": "ListItem", "position": 4, "name": "Encéphalopathies", "item": "https://questionsmedicales.fr/mesh/D001927" }, { "@type": "ListItem", "position": 5, "name": "Épilepsie", "item": "https://questionsmedicales.fr/mesh/D004827" }, { "@type": "ListItem", "position": 6, "name": "Syndromes épileptiques", "item": "https://questionsmedicales.fr/mesh/D000073376" }, { "@type": "ListItem", "position": 7, "name": "Épilepsies myocloniques", "item": "https://questionsmedicales.fr/mesh/D004831" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Épilepsies myocloniques - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Épilepsies myocloniques", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Épilepsies myocloniques", "description": "Comment diagnostiquer une épilepsie myoclonique ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent une épilepsie myoclonique ?\nL'épilepsie myoclonique est-elle héréditaire ?\nQuel rôle joue l'EEG dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Ganoderma&page=20#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Épilepsies myocloniques", "description": "Quels sont les symptômes principaux ?\nLes myoclonies sont-elles douloureuses ?\nPeut-on avoir des crises sans myoclonies ?\nLes symptômes varient-ils d'une personne à l'autre ?\nLes crises peuvent-elles survenir la nuit ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Ganoderma&page=20#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Épilepsies myocloniques", "description": "Peut-on prévenir les crises myocloniques ?\nQuels déclencheurs sont à éviter ?\nL'éducation est-elle importante pour la prévention ?\nLe suivi médical est-il essentiel ?\nLes activités physiques sont-elles sûres ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Ganoderma&page=20#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Épilepsies myocloniques", "description": "Quels médicaments sont utilisés pour traiter ?\nY a-t-il des traitements non médicamenteux ?\nComment évaluer l'efficacité du traitement ?\nLes traitements sont-ils à vie ?\nQuels effets secondaires des médicaments ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Ganoderma&page=20#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Épilepsies myocloniques", "description": "Quelles complications peuvent survenir ?\nL'épilepsie myoclonique peut-elle affecter la vie quotidienne ?\nY a-t-il un risque accru de dépression ?\nLes crises peuvent-elles entraîner des accidents ?\nComment gérer les complications psychologiques ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Ganoderma&page=20#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Épilepsies myocloniques", "description": "Quels sont les facteurs de risque connus ?\nL'âge influence-t-il le risque d'épilepsie myoclonique ?\nLes troubles neurologiques augmentent-ils le risque ?\nLe stress est-il un facteur de risque ?\nLes infections cérébrales sont-elles un risque ?", "url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Ganoderma&page=20#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une épilepsie myoclonique ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique médical, l'examen neurologique et l'EEG." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "L'EEG, l'IRM cérébrale et des tests sanguins peuvent être utilisés." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent une épilepsie myoclonique ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des secousses musculaires rapides, souvent sans perte de conscience, sont typiques." } }, { "@type": "Question", "name": "L'épilepsie myoclonique est-elle héréditaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Certaines formes peuvent être héréditaires, nécessitant une évaluation familiale." } }, { "@type": "Question", "name": "Quel rôle joue l'EEG dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'EEG aide à détecter les anomalies électriques typiques des épilepsies myocloniques." } }, { "@type": "Question", "name": "Quels sont les symptômes principaux ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des myoclonies, des crises généralisées et parfois des absences." } }, { "@type": "Question", "name": "Les myoclonies sont-elles douloureuses ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les myoclonies ne sont généralement pas douloureuses, mais peuvent être gênantes." } }, { "@type": "Question", "name": "Peut-on avoir des crises sans myoclonies ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines personnes peuvent avoir des crises généralisées sans myoclonies." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'une personne à l'autre ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la fréquence des symptômes peuvent varier considérablement." } }, { "@type": "Question", "name": "Les crises peuvent-elles survenir la nuit ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des crises myocloniques peuvent survenir pendant le sommeil." } }, { "@type": "Question", "name": "Peut-on prévenir les crises myocloniques ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par un traitement adéquat et l'évitement des déclencheurs." } }, { "@type": "Question", "name": "Quels déclencheurs sont à éviter ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, la fatigue, et la consommation d'alcool peuvent déclencher des crises." } }, { "@type": "Question", "name": "L'éducation est-elle importante pour la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation sur la maladie aide les patients à mieux gérer leur condition." } }, { "@type": "Question", "name": "Le suivi médical est-il essentiel ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier permet d'ajuster le traitement et de surveiller les symptômes." } }, { "@type": "Question", "name": "Les activités physiques sont-elles sûres ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines activités peuvent être sûres, mais il faut éviter les sports à risque." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour traiter ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les anticonvulsivants comme le valproate et le lamotrigine sont couramment prescrits." } }, { "@type": "Question", "name": "Y a-t-il des traitements non médicamenteux ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme la thérapie comportementale et la diététique peuvent aider." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité du traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par la réduction des crises et les effets secondaires." } }, { "@type": "Question", "name": "Les traitements sont-ils à vie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Souvent, le traitement est à long terme, mais certains peuvent réduire ou arrêter." } }, { "@type": "Question", "name": "Quels effets secondaires des médicaments ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires peuvent inclure fatigue, vertiges et troubles gastro-intestinaux." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des blessures dues aux crises et des troubles psychologiques." } }, { "@type": "Question", "name": "L'épilepsie myoclonique peut-elle affecter la vie quotidienne ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut impacter la vie sociale, professionnelle et la qualité de vie." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de dépression ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes épileptiques ont un risque plus élevé de dépression et d'anxiété." } }, { "@type": "Question", "name": "Les crises peuvent-elles entraîner des accidents ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les crises peuvent provoquer des accidents, notamment lors de la conduite." } }, { "@type": "Question", "name": "Comment gérer les complications psychologiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Un soutien psychologique et des thérapies adaptées peuvent aider à gérer ces complications." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque connus ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux, les traumatismes crâniens et certaines infections sont des facteurs." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'épilepsie myoclonique ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'épilepsie myoclonique peut débuter à tout âge, mais souvent dans l'enfance ou l'adolescence." } }, { "@type": "Question", "name": "Les troubles neurologiques augmentent-ils le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, d'autres troubles neurologiques peuvent augmenter le risque d'épilepsie myoclonique." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut déclencher des crises chez les personnes prédisposées." } }, { "@type": "Question", "name": "Les infections cérébrales sont-elles un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections, comme la méningite, peuvent augmenter le risque d'épilepsie." } } ] } ] }

Sources (195 au total)

Ganoderma microsporum immunomodulatory protein acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 by interfering virus binding to the host cells and spike-mediated cell fusion.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible coronavirus that has caused over 6 million fatalities. SARS-CoV-2 variants with spike mutations are frequently en... ACE2-overexpressing HEK293T cells (HEK293T/ACE2) and SARS-CoV-2 pseudoviruses carrying spike variants were used to study the effects of GMI in vitro. Infectivity was evaluated by fluorescence microsco... GMI broadly blocked SARS-CoV-2 infection in various cell lines. GMI effectively inhibited the infection of pseudotyped viruses carrying different emerged spike variants, including Delta and Omicron st... GMI, an FDA-approved dietary ingredient, acts as a multifunctional broad-spectrum antiviral against SARS-CoV-2 and could become a promising candidate for preventing or treating SARS-CoV-2 associated d...

A novel mucosal bivalent vaccine of EV-A71/EV-D68 adjuvanted with polysaccharides from Ganoderma lucidum protects mice against EV-A71 and EV-D68 lethal challenge.

Human enteroviruses A71 (EV-A71) and D68 (EV-D68) are the suspected causative agents of hand-foot-and-mouth disease, aseptic meningitis, encephalitis, acute flaccid myelitis, and acute flaccid paralys... In this study, formalin-inactivated EV-A71 and EV-D68 were used as antigens, while PS-G, a polysaccharide from Ganoderma lucidum, was used as an adjuvant. Natural polysaccharides have the characterist... The EV-A71 + EV-D68 bivalent vaccine generated considerable EV-A71- and EV-D68-specific IgG and IgA titres in the sera, nasal washes, saliva, bronchoalveolar lavage fluid, and feces. These antibodies ... These findings demonstrated that PS-G can be used as a potential adjuvant for EV-A71 and EV-D68 bivalent mucosal vaccines. Our results provide useful information for the further preclinical and clinic...

Synergy of de-walled Ganoderma Lucidum spore powder (GLSP) on targeted therapy in advanced non-squamous non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutant: protocol for a randomized, double-blind, placebo-controlled study.

Osimertinib is regarded as a promising third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for advanced non-squamous non-small cell lung cancer (NSCLC) patients wh... A total of 140 participants will be randomly assigned to receive either de-walled GSLP or placebo for a duration of 56 days. The primary outcome measure is the fatigue score associated with EGFR-TKI a... China Clinical Trial Registry ChiCTR2300072786. Registrated on June 25, 2023....